# **Special Issue**

# Metabolic Modulators in Cardiovascular Disease Management

# Message from the Guest Editor

Cardiovascular disease is the number one cause of death worldwide and we need new therapies that modulate metabolism. This Special Issue is all about the latest research on metabolic modulators in cardiovascular disease, from basic science to clinical applications. We are looking at how metabolic pathways can be targeted to prevent, treat and manage cardiovascular conditions. The scope includes, but is not limited to, new metabolic drug targets, mitochondrial function modulators, metabolic syndrome interventions and new therapeutic strategies. We are interested in research on the role of metabolic regulators in heart failure, atherosclerosis and cardiometabolic disorders. We also want to see studies on the intersection of metabolism with inflammation, oxidative stress and energy homeostasis in cardiovascular disease. Submit your latest research on metabolic approaches to cardiovascular disease here. New therapeutic targets. clinical trials of metabolic modulators and new diagnostic approaches are especially welcome. Original research and reviews are both accepted, especially on emerging therapies.


## **Guest Editor**

Dr. Syed Siraj A. Quadri

Faculty of Pharmacology, Lincoln Memorial University, Debusk College of Osteopathic Medicine, 9737 Cogdill Road, Knoxville, TN 37932, USA

## Deadline for manuscript submissions

31 August 2025



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/224114

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/ metabolites





# Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

## Editor-in-Chief

#### Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

## **Author Benefits**

# **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

